Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus

類似資料

• Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus
  著者:: Yao, Yihong, 等
  出版事項: (2009)
• A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
  著者:: Higgs, Brandon W, 等
  出版事項: (2014)
• Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus
  著者:: Narwal, Rajesh, 等
  出版事項: (2013)
• Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study: A Phase I Randomized, Controlled, Dose-Escalation Study
  著者:: Petri, Michelle, 等
  出版事項: (2013)
• Efficacy of sifalimumab for treatment of skin injury caused by systemic lupus erythematosus
  著者:: Huo, Ai-xin, 等
  出版事項: (2019)